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Background. Chlamydia trachomatis, an obligate intracellular pathogen, is a leading worldwide cause of ocular and urogenital
diseases. Advances have been made in our understanding of the nine-member polymorphic membrane protein (Pmp) gene
(pmp) family of C. trachomatis. However, there is only limited information on their biologic role, especially for biological
variants (biovar) and clinical strains. Methodology/Principal Findings. We evaluated expression for pmps throughout
development for reference strains E/Bour and L2/434, representing different biovars, and for clinical E and L2 strains.
Immunoreactivity of patient sera to recombinant (r)Pmps was also determined. All pmps were expressed at two hours. pmpA
had the lowest expression but was up-regulated at 12 h for all strains, indicating involvement in reticulate body development.
For pmpD, expression peaked at 36 h. Additionally, 57.7% of sera from infected and 0% from uninfected adolescents were
reactive to rPmpD (p=0.001), suggesting a role in immunogenicity. pmpF had the highest expression levels for all clinical
strains and L2/434 with differential expression of the pmpFE operon for the same strains. Sera were nonreactive to rPmpF
despite immunoreactivity to rMOMP and rPmpD, suggesting that PmpF is not associated with humoral immune responses.
pmpFE sequences for clinical strains were identical to those of the respective reference strains. We identified the putative
pmpFE promoter, which was, surprisingly, 100% conserved for all strains. Analyses of ribosomal binding sites, RNase E, and
hairpin structures suggested complex regulatory mechanism(s) for this .6 Kb operon. Conclusions/Significance. The
dissimilar expression of the same pmp for different C. trachomatis strains may explain different strain-specific needs and
phenotypic distinctions. This is further supported by the differential immunoreactivity to rPmpD and rPmpF of sera from
patients infected with different strains. Furthermore, clinical E strains did not correlate with the E reference strain at the gene
expression level, reinforcing the need for expansive studies of clinical strains.
Citation: Nunes A, Gomes JP, Mead S, Florindo C, Correia H, et al (2007) Comparative Expression Profiling of the Chlamydia trachomatis pmp Gene
Family for Clinical and Reference Strains. PLoS ONE 2(9): e878. doi:10.1371/journal.pone.0000878
INTRODUCTION
Chlamydia trachomatis is an obligate intracellular pathogen that is
responsible for significant worldwide morbidity associated with
ocular and sexually transmitted diseases (STD). The developmen-
tal cycle of the organism is biphasic beginning with the adhesion of
the elementary body (EB), an infectious and metabolically inert
form, to the host cell. After endocytosis, the EB differentiates ,2
to 12 h post infection (p.i.) into a larger, non-infectious and
metabolically active reticulate body (RB), which initiates in-
tracellular replication by binary fission within a vacuole called an
inclusion body. At ,30 to 36 h p.i., RBs reorganize into new EBs,
which are released by host cell lysis or exocytosis at 48 to 72 h p.i.
that initiates another infectious cycle [1,2].
The disease spectrum of C. trachomatis ranges from conjunctivitis
and ocular trachoma to tubal factor infertility, ectopic pregnancy
and infant pneumonitis [3,4]. C. trachomatis serological variants
(serovars) are grouped within two human biological variants
(biovars) according to characteristics of disease presentation: the
trachoma biovar, including serovars A to C and Ba, which cause
conjunctivitis and trachoma, and serovars D to K and Ba, Da, Ia
and Ja, which cause conjunctivitis, urogenital infections and infant
pneumonitis, and the lymphogranuloma venereum (LGV) biovar
(serovars L1 to L3 and L2a). The latter serovars are more invasive,
causing genital ulceration, lymphadenitis and proctitis [3,5].
However, serotyping of the major outer membrane protein
(MOMP), and phylogenetic reconstructions of this protein and
the corresponding gene (ompA) [6,7] do not group serovars by
trachoma, non-invasive urogenital or invasive LGV disease
groups.
The molecular mechanisms behind these biological differences
among serovars (or strains) are not well understood. Genome
sequences of reference strains D/UW-3 [8] and A/Har-13 [9], as
well as ongoing C. trachomatis genomic sequencing are providing
information on specific genes and proteins that may explain tissue
tropism and virulence differences for the three disease groups. C.
trachomatis contains a partial tryptophan operon (trpRBA) where
urogenital strains, but not trachoma strains, can synthesize
tryptophan from mucosal substrates [10]. The toxin gene possesses
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domain for the urogenital strains but not for trachoma or LGV
strains [11].
Research on the nine member polymorphic membrane protein
(Pmp) gene (pmp) family has revealed phylogenetic reconstructions
where six pmps( pmpB, pmpC, pmpF, pmpG, pmpH and pmpI) form
clades that correspond to the three disease groups [12–14]. At the
gene expression level, previous RT-PCR analyses of reference
strains D/UW-3 and L2/434 [15], and microarray analysis of D/
UW-3 [16] found that all nine pmps were transcribed starting at
8 h p.i. Yet, based on real-time quantitative (k)RT-PCR, we found
expression as early as 2 h p.i. for pmpC for reference strains Ba/
Apache-2, G/UW-57 and L2/434, and a differential expression
profile with earlier up-regulation of pmpC for L2/434 [17]. Also,
another study based on kRT-PCR, Kiselev et al. [18] detected
pmpD expression as early as 2h p.i. for L2/434. Proteomics analyses
have also shown that all Pmps of L2/434 are detected as outer
membrane constituents [19–22]. There is also evidence that some
Pmps are antigenic for human sera [15,23]. We observed
a heterogeneous immunoreactivity to recombinant (r)PmpC using
sera from patients infected with different C. trachomatis strains,
suggesting a role for PmpC in antigenic variation [17]. More
recently, Pmps have been considered autotransporters based on
bioinformatics analyses [24,25]. Wehrl et al. [26] has experimen-
tally demonstrated the autotransporter model for the C. pneumoniae
ortholog of C. trachomatis PmpD, Pmp21. Further, using immuno-
fluorescence microscopy, Western blotting and penicillin treat-
ment, the results of Kiselev et al. [18] for L2/434 PmpD are in
general agreement with the autotransporter model for this protein.
PmpD has also been shown to be a species-common neutralizing
antigen [27], while PmpF has been implicated as a potential target
of the host immune response as it contains several predicted major
histocompatibility (MHC) epitopes within the N-terminal domain
[9].
Despite the potential importance of Pmps in chlamydial biology,
there is a lack of expression data for the pmp genes as well as an
insufficient understanding of the host immune response to their
proteins. Here, we profile the expression of all pmps throughout
development for reference strains E/Bour and L2/434, represent-
ing the two C. trachomatis biovars. We chose E/Bour because it is
the most prevalent strain worldwide, although the mechanisms of
its ecological success are not yet understood. L2/434 was selected
as it has been widely studied with a plethora of biological
information for comparative analyses. The biological uniqueness
of these two strains in vivo is reflected in their differential tissue
tropism, virulence and disease presentation. In light of our recent
findings that reference strains do not represent the same genetic
composition of clinical strains that are circulating among human
populations today [28], we also compared the nine pmp expression
levels for four C. trachomatis clinical strains, representing ompA
genotypes of E and L2. Further, we examined the immunoreac-
tivity of sera from adolescents with and without C. trachomatis
urogenital infections against rPmps to further define their potential
importance in human disease.
MATERIALS AND METHODS
C. trachomatis cell culture of reference strains and
clinical strains
C. trachomatis reference strains E/Bour and L2/434, three clinical
strains belonging to ompA genotype E (designated as E/537C-05,
E/S-141 and E/CS-500-96) and one clinical strain belonging to
ompA genotype L2 were evaluated in this study. E/537C-05 and E/
S-141 were collected from patients with vaginal discharge, E/CS-
500-96 from a patient with cervicitis, and L2 from a patient with
proctitis. Each was propagated in HeLa 229 cell monolayers using
standard techniques as previously described [4,29]. EBs were
harvested at 48–72 h p.i. and purified by discontinuous density
centrifugation in Renografin [30].
Confluent HeLa cells were either mock-infected or infected with
a multiplicity of infection of one for each reference strain or
clinical strain in SPG prior to incubation with culture medium
[4,29]. Eight T25 flasks (one for each time point of 2, 6, 12, 18, 24,
36, and 48 h and mock-infected) per strain were inoculated and
placed at 37uCi n5 %C O 2 [17]. Cultured cells were harvested at
each time point, and total RNA was extracted as previously
described [17].
Reverse Transcription and Quantitative Real-Time
PCR (kPCR)
RNA was quantified by O.D. measured at A260. cDNA was
generated from 500 ng of each RNA sample using TaqMan RT
Reagents (Applied Biosystems, Foster City, CA) and random
hexamers, and was quantified by O.D. measured at A260.
Quantitation of pmp expression was achieved using the ABI
7000 SDS (Applied Biosystems), SYBR Green chemistry, and the
standard curve method for relative quantitation, using reagents
and thermocycling as previously described [17]. 16SrRNA was used
as the endogenous control since normalizing the data against
16SrRNA provides a control for the number of organisms (EBs and
RBs) and, therefore, for the differential growth rate of each strain.
ompA was included as a quality control for kRT-PCR results since
it has been widely used for gene expression studies [16,17].
Primers for each of the nine pmps (Table 1) were designed using
Primer Express (Applied Biosystems). Primers for ompA, 16SrRNA,
and pmpC were used as previously designed (Table 1) [17].
Each plate contained two replicates of each sample cDNA,
three different negative controls and standard curves for each gene
as previously described (17). For all experiments, the amount of
target and control gene was determined from the respective
standard curve by conversion of the mean threshold cycle values.
Normalization was obtained by dividing the quantity of the target
gene by the quantity of the control gene. The specificity of the
amplified products was verified by analysis of the dissociation
curves generated by the ABI7000 software based on the specific
melting temperature for each amplicon. The results were based on
three independent experiments for reference strains E/Bour and
L2/434, and for the four clinical strains.
Genetic analysis of the pmpFE operon for C.
trachomatis reference and clinical strains
Based on the considerable expression disparities between pmpF and
pmpE (which belong to the same operon) for reference strain L2/
434 and mostly for the clinical strains (see results below), we
sequenced the pmpFE operon as well as the upstream 164 base pair
(bp) pmpG/pmpF intergenomic region (IGR) that likely contains the
operon regulatory region. In the C. trachomatis chromosome, pmpF
and pmpE are located on the minus strand; pmpF is located
upstream of pmpE, with a 2 bp IGR . pmpE was sequenced for the
six strains (Genbank Accession Numbers EF490370 for E/537C-
05, EF490371 for E/CS-500-96, EF490372 for E/S-141,
EF490373 for L2, EF490374 for E/Bour, and EF490375 for
L2/434), while pmpG/pmpF IGR and pmpF were sequenced only
for the clinical strains (Genbank Accession Numbers EF490366 for
L2, EF490367 for E/CS-500-96, EF490368 for E/S-141, and
EF490369 for E/537C-05), as the sequences for the reference
strains were available from our previous study (GenBank
C. trachomatis pmp Expression
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434) [12]. The amplification and sequencing strategies were
performed as previously described [12], except for the pmpG/pmpF
IGR, where we used primer 59-ACT CGG ATC TCC TAT AAC
AG-39 for sequencing.
Since the transcription process can be strongly affected by the
structure and sequence variability of promoter regions [31–34],
a putative promoter search for the pmpFE operon was performed
using EditSeq software (DNASTAR, Madison, WI) for sequences
described in the literature and also by using two promoter
prediction programs: http://www.fruitfly.org/seq_tools/promot-
er.html and http://www.prodoric.de/vfp/vfp_promoter.php.
Given the expression dissimilarities obtained in this study for
pmpF and pmpE, we searched for putative Shine-Dalgarno
ribosome binding sequences (RBS) [35] as well as previously
described chlamydial RBS [36–39] within this operon, since
ribosomes can either prolong or shorten the lifetime of mRNA in
response to events that occur during translation or termination
processes [40]. The existence of putative consensus cleavage sites
for RNase E [41–43], the major endonuclease that generally
initiates mRNA degradation in most bacteria [44], was also
examined within the pmpFE operon. These two analyses were
performed using EditSeq software (DNASTAR). Putative stem-
loop structures were searched throughout the pmpFE operon using
GeneQuest software (DNASTAR) and RNAstructure software
version 4.4 (http://rna.urmc.rochester.edu/rnastructure.html) due
to the regulatory or processing role of stem-loop structures in
premature transcription termination as well as in mRNA
degradation and maturation mechanisms [45–49], respectively.
Immunoreactivity of patient sera against Pmp fusion
proteins
We generated fusion proteins for PmpD and PmpF because the
latter displayed such high mRNA expression for L2/434 and the
clinical strains, and the former was expressed late in development
for all strains under study, being the last up-regulated protein for
four of the six strains analyzed. Also, PmpD has been associated
with neutralizing epitopes [27]. The rMOMP fusion protein was
available from a previous study [50]. The PET30 expression
system (EMD Biosciences, San Diego, CA) was used for cloning
PCR products containing pmpD or pmpF generated from strain E/
Bour genomic DNA as we have described [17]. The forward and
reverse primers were 59-GACGACGACAAGATGAGTTCCGA-
GAAAGATATA-39 and 59-AATGCTGGATTGCGATTGATC-
TTTTAACCGGGCTTCTCCTC-39 for pmpD, respectively, and
59-GACGACGACAAGATGATTAAAAGAACTTCTCTA-39 and
59-AATGCAGGAGGAGCTCTGGTCTTTTAACCGGGCTTC-
TCCTC-39 for pmpF, respectively. Sequencing confirmed that the
insert was in frame with the S-tag and His-tag as we have described
Table 1. Oligonucleotide primers used for kRT-PCR
..................................................................................................................................................
Gene Primers Primer sequence (59 to 39) Gene Location Base pair size
pmpA pmpA-3
a TGCTAGGGAAGATGTTGCAAATAG 1434–1457 51
pmpA-4
a TGAACGGGTTGGTTAAAAATCG 1484–1463
pmpB pmpB-5
a CGACTATCAGCAAAAACACTGCTAA 2120–2144 102
pmpB-6
a TAGCGGAGTTCTCAGAGATATTCAGTT 2221–2195
pmpC pmpC-11
a TTAGTGCTCCCTACAGACTCATCAA 4150–4174 56
pmpC-12
a CCCGTCAGTACTATTTTCTGAGCTT 4205–4181
pmpD pmpD-3
a GCGTGTCGCTCTGGAAAATAAT 4455–4476 51
pmpD-4
a ACTGTGCTGAAGTAAGAACTCCATTC 4505–4480
pmpE pmpE-1
a CATATGCGCTCTTCCGGATAC 2140–2160 51
pmpE-2
a GTGTGTCTGCCCTGCTATCATC 2190–2169
pmpF pmpF-5
a TCCTATGTTTGATCGCATTGCT 2520–2541 69
pmpF-6
a CTCCGCATGTTATGTGTTCCA 2588–2566
pmpG pmpG-1
a, b TGGGTTTCTGGAGTTTCGAATT 2221–2242 51
pmpG-2
a, b ACCTAAAGCATCGCGGTCAT 2271–2252
pmpG-3
a TGTGGCCCTGTACAATTCTTAGG 1165–1187 52
pmpG-4
a AAATCGCTCCACCATCATTAGC 1216–1195
pmpH pmpH-15
a TGCATACGCAGTATTTTAATGACAAA 2486–2511 61
pmpH-16
a TGCCAATGACATTTCGAATGAT 2546–2525
pmpI pmpI-1
a GGAGAAGTGTGCGCATCGAT 2176–2195 51
pmpI-2
a GAACAGTCCGGAACCATTGG 2226–2207
ompA OmpA-9
c TGCCGCTTTGAGTTCTGCTT 33–52 75
OmpA-10
c GTCGATCATAAGGCTTGGTTCAG 108–86
16SrRNA 16SRNA-9
d GCGAAGGCGCTTTTCTAATTTAT 734–756 76
16SRNA-10
d CCAGGGTATCTAATCCTGTTTGCT 809–786
aPrimers designed based on each pmp sequence of reference strains E/Bour and L2/434 [12].
bPrimers designed only for strain L2.
cPrimers designed based on the ompA sequence of reference strains E/Bour and L2/434 (GenBank Accession No. X52557 and M14738, respectively).
dPrimers designed based on the 16SrRNA sequence of reference strains E/Bour and L2/434 (GenBank Accession No. D85722 and U68443, respectively).
doi:10.1371/journal.pone.0000878.t001
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
C. trachomatis pmp Expression
PLoS ONE | www.plosone.org 3 September 2007 | Issue 9 | e878previously for rPmpC [17]. The clones were transformed into E. coli
BL21 and induced using 0.1mM IPTG during the exponential growth
phase. Ni-agarose (Sigma, St. Louis, MO) was used for fusion protein
purification according to the package insert. Recombinant proteins
were determined to be the correct molecular weight (calculated at
,160.6 kDa for rPmpD and ,112.3 kDa for rPmpF) by immunoblot
using AP-conjugated S-protein, which binds to the S-tag peptide with
a distinct band at the correct molecular weight for each. Optimal
protein concentrations were determined and standardized using BCA
(Pierce, Rockford, Ill) before analyzing the clinical sera. The optimal
protein concentration for rPmpD was 50 ng and 100 ng for rPmpF.
Sera from 39 consented female adolescents 14 to 19 years of age
attending clinics in Oakland, CA, were used at a 1:50 dilution for
immunoblotting as described previously [17]. The Institutional
Review Board of Children’s Hospital Oakland approved the study,
and all patients provided written consent for all clinical samples that
were obtained and used in this study. The blots were blocked with
Blotto prior to reacting with patient sera and alkaline phosphatase-
conjugated anti-human IgG (R&D Systems, Minneapolis, MN). The
chemifluorescent substrate ECF (Amersham, Piscataway, NJ) was
used to visualize reactive bands. Twenty six (67%) of the 39
adolescents were infected with a single ompA genotype: 3 Ba, 3 D, 8
E ,5F ,1G ,1I a ,2J ,a n d3K .
There was no evidence for mixed infections. The original
cervical samples were used for sequencing (see ref 17) to best
determine the presence of a mixed infection, since propagation
may result in one strain overgrowing another. On inspection of the
electropherograms, none of the samples had ambiguous results. All
nucleotides were represented by single, clear peaks with extremely
low background and without evidence for double peaks in
a nucleotide position where different ompA genotypes differ, which
might suggest a mixed infection.
RESULTS
Real-time quantitation for pmp expression
The results of specificity assays revealed no non-specific products,
and indicated the presence of the expected amplicon for each
gene. Standard curves for all 11 genes had slope values between -
3.1 and -3.5, which represents efficiencies between 93 and 100%.
There were only minor variations in the slope for each standard
curve among independent experiments, indicating a highly re-
producible kPCR as we have also shown in previous experiments
[17]. We defined the gene expression profile as the qualitative gene
expression pattern throughout development where quantitative
values are not considered. For example, one expression profile
would show increasing expression up to a peak with tapering down
of the expression after the peak. An expression peak was defined as
the time point of the highest relative mRNA value. All quantitative
expression comparisons refer to differences between the expression
peak of each gene, even those occurring at different time points p.i.
Expression profile of the nine pmp genes
throughout development for E/Bour and L2/434
L2/434 had strikingly different mRNA levels among some pmps
and also between different time points for the same pmp (Fig. 1A).
pmpF had the highest relative mRNA expression, up to 11.5-fold
higher than for pmpA, the least expressed gene. mRNA levels were
detected at 2 h p.i. for all pmps, including pmpA where the scale
limits visualization of the low mRNA expression, and peaked at
different time points. For all pmps except pmpA, mRNA levels
decreased consistently after the peak until 48 h.
The pmp expression profiles for E/Bour were more homoge-
neous than for L2/434, and, in some cases, mRNA levels were
lower than for the corresponding L2/434 pmp (Fig. 1B). Similar to
L2/434, mRNA levels were detected at 2 h p.i. for all pmp genes.
pmpE, pmpF and pmpG showed the highest expression levels for
strain E/Bour with up to 3.1-fold higher mRNA levels than for
pmpA and pmpI, the least expressed genes. As for L2/434, pmpA and
pmpD were the earliest and the latest up-regulated genes,
respectively. In contrast to L2/434, all pmp genes except pmpA
and pmpI had stable mRNA levels after the expression peak until
48 h. For this reason, the expression peak for E/Bour pmps was
defined as the time point at which a noticeable expression increase
occurred.
For both reference strains, ompA had remarkably higher mRNA
values at all time points than for the pmps (Fig. 1). In contrast to
most pmps, ompA revealed a similar gene expression profile for both
reference strains.
Expression profile of the nine pmp genes
throughout development for C. trachomatis clinical
strains
The four clinical strains had a similar pmp expression profile
(Fig. 2), which showed decreasing mRNA levels after the
expression peak to 48 h. mRNA levels were detected at 2 h p.i.
for all pmps, although the scale limits visualization. Overall, pmps
peaked at 18h for L2 (Fig. 2A) and E/CS-500-96 (Fig. 2D), and at
36h for clinical strains E/537C-05 (Fig. 2B) and E/S-141 (Fig. 2C).
Similar to reference strains E and L2, pmpA was the first up-
regulated gene for all clinical strains. In addition, pmpD was the last
up-regulated gene for clinical strains L2 and E/CS-500-96 (Fig. 2A
and 2D), and was also expressed late in development (together
with other pmps) for the other two clinical E strains under study.
pmpF had the highest expression among all of the pmps for the
clinical strains (Fig. 2). In fact, there was a 27-fold higher
expression of pmpF compared with the least expressed gene (pmpD)
for L2. For clinical E strains, there was a 19.2- and 22.6-fold higher
expression of pmpF compared with the least expressed gene (pmpI)
for E/537C-05 and E/CS-500-96 respectively, and a 54.2-fold
higher expression than pmpA for E/S-141 Although no relevant
dissimilarities were observed for pmpF between clinical L2 and L2/
434, there were considerable expression differences among the
clinical strains and E/Bour with up to 11.7-fold higher mRNA
values for E/CS-500-96 than for E/Bour.
For ompA, mRNA levels peaked at 36 h for E/537C-05 and E/
S-141, and at 18h for E/CS-500-96 and L2, declining thereafter
(Fig. 2). The most striking example of differential mRNA levels
between ompA and pmps occurred for E/S-141, where ompA had
a 232.0-fold higher value compared with the least expressed gene,
pmpA. However, all clinical strains except E/CS-500-96 had lower
ompA expression levels for all time points compared with the
corresponding reference strains.
Genetic analysis of pmpFE operon for C. trachomatis
reference strains and clinical strains
The pmpF, pmpE and pmpG/pmpF IGR sequences for the three
clinical E strains were 100% similar to the corresponding E/Bour
sequences, while L2 showed 4 nucleotide (nt) differences to L2/434
but only for pmpE. Compared to both L2 strains, the four E strains
showed 317 (10.2%) nt and 106 (10.3%) amino acid (aa)
differences for pmpF as well as 56 (1.9%) nt and 21 (20 to L2)
(2.1%) aa differences for pmpE. For the pmpG/pmpF IGR, which
comprises the ,164 bp upstream region of pmpF, there were 5 nt
differences between the L2 and the E strains, although none of
them fell within the putative promoter region for the pmpFE
C. trachomatis pmp Expression
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conserved stretch of the pmpG/pmpF IGR for both reference and
all clinical strains (Fig. 3). The -10 promoter element (TAAAAT)
identified in this study was identical to the one that was previously
characterized for the L2/434 and D/UW-3 ltuB promoter, while
the -35 region (TTGCAT) was 100% similar to the hctA promoter
of the same chlamydial reference strains [32].
Analysis of the pmpFE operon sequence revealed several putative
hairpin loop structures although the actual RNA folding in those
regions functioning as a classic rho-independent type transcrip-
tional terminator [49] cannot be assumed. At least 41 putative
RNase E cleavage sites were identified throughout the pmpFE
operon, 13 of which were not conserved between L2/434 (and L2)
and the four E strains (Fig. 4). One of these non-conserved sites
involved the pmpF/pmpE IGR, and is specific for the E strains. The
search for an RBS revealed a perfect prokaryotic Shine-Dalgarno
sequence (AGGAGG) located 17 nts upstream of the start codon
of pmpE, which is approximately 3000 bp below the last bp in
Figure 3 and, therefore, is not shown. This RBS is in close
proximity to the above-described putative RNase cleavage site
shared only by the four E strains. However, the best approach for
a putative RBS sequence for pmpF has two mismatches when
compared with the ones described in the literature, and is
unusually distant from the start codon (Fig. 3). Two additional
putative RNase E cleavage sites, one of which was in close
proximity to this RBS, were identified within the pmpF regulatory
region (Fig. 3).
Immunoreactivity of patient sera with Pmp fusion
proteins
Table 2 shows the clinical and microbiologic characteristics of the
39 adolescents enrolled in the study and the results of their serum
immunoreactivity to rPmpD and rPmpF. All sera from patients
infected with chlamydial clinical strains Ba, E, F and K (n=15;
57.7%), but none with D, Ia, J or G (n=11; 42.3%), were reactive
to rPmpD while sera from uninfected patients were nonreactive
with rPmpD (p=0.001). Figure 5 shows the immunoblot results of
representative sera from patients infected with Ba, D, E, F, G, Ia, J
and K to rPmpD. Because pmpD is highly conserved among all
Figure 1. Expression profile of the nine pmp genes and ompA throughout the development of C. trachomatis. Reference strain L2/434 is
represented in panel A and E/Bour in panel B. Values represent the mean6SEM based on three independent experiments for time points of 2, 6, 12,
18, 24, 36, and 48 h post infection. See methods for details.
doi:10.1371/journal.pone.0000878.g001
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sequence of reference strain E/Bour should not have contributed
to the observed differences in immunoreactivity. Further, cross-
reactivity between strains was unlikely since the patients were
infected with only a single strain, and sera that were reactive to
rPmpD were not reactive to rPmpF. In our previous study, sera
form the same individuals infected with clinical strains D, E and G
reacted with rPmpC [17]. Surprisingly, none of the sera reacted to
Figure 2. Expression profile of pmp and ompA genes throughout the development of C. trachomatis clinical strains. (A) Strain L2 shares the same
ompA genotype as L2/434; and strains E/537C-05 (B), E/S-141 (C) and E/CS-500-96 (D) share the same ompA genotype as E/Bour. Values represent the
mean6SEM based on three independent experiments for time points of 2, 6, 12, 18, 24, 36, and 48 h post infection. See methods for details.
doi:10.1371/journal.pone.0000878.g002
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with strain E, although all sera from infected patients and one
uninfected patient reacted with rMOMP as previously shown [17].
DISCUSSION
In this study, we determined the gene expression profile of the nine
pmps throughout development for reference strains L2/434 and E/
Bour, and four clinical strains belonging to ompA genotypes E and
L2. The reference strains had significant gene expression
differences where E/Bour had relatively lower mRNA levels and
generally sustained expression from 24 to 48 h compared with L2/
434 (Fig. 1). Surprisingly, in contrast to clinical L2, the three
clinical E strains showed a dissimilar pmp expression profile to E/
Bour (Fig. 2). These remarkable expression dissimilarities are
generally supported by our recent comparative genomics findings
where the laboratory adapted reference strains did not reflect the
same genetic make-up of strains that are circulating among human
populations today and currently exposed to immune selection
[28].
It is well known that the developmental stages for reference E
strains occur at later time points than for reference L2 strains [51].
This is supported by the ompA expression for E/Bour, which is
shifted ,6 hours later than for L2/434. However, the differential
growth rate between these two reference strains does not explain
the dissimilar pmp expression, as most pmps were up-regulated at
the same time point for both (Fig. 1). For E/Bour, almost all of the
pmps had increased expression during the second half of
development with comparable mRNA levels at these stages,
suggesting a similar involvement in RB division and RB to EB
transformation. For L2/434, although most pmps showed a general
up-regulation of transcription at the exponential growth phase of
RB division when new membranes are being formed, pmpC, pmpE
and pmpF appeared to play a more important role during this
phase. Thus, the gene expression results of both E/Bour and L2/
434 suggest their potential importance in membrane integrity.
However, some Pmps may have more specific functions than
others, depending on the chlamydial strain. In support of this,
a proteomics study by Shaw et al. [21] detected five Pmps among
reference strains A/HAR-13, D/UW-3, and L2/434, where PmpF
was only detected for L2/434. In another proteomics study, only
pmpE, pmpG, and pmpH were detected for L2/434 [22]. However, it
is possible that these studies reflect a lack of sensitivity in detecting
Pmps since a recent study was able to detect all Pmps for L2/434
[19].
Interestingly, pmpA had, in general, the lowest expression levels
of all pmps at each time point except that it had one of the highest
levels at 12 h p.i. (Fig. 1 and 2), suggesting a greater importance of
PmpA during early stages of development. This is supported by
shotgun proteomics where Skipp et al. [19] identified PmpA
exclusively in RBs, whereas all other Pmps were detected in both
RBs and EBs for L2/434. Additionally, for PmpD, the late up-
regulation at 36 h corresponds to RB transformation into EBs,
suggesting a role in EB outer membrane structure. In support of
this, PmpD has a cysteine content considerably higher than any
other Pmp [12]. There are 26 conserved cysteine residues in
PmpD for all 19 C. trachomatis reference strains, while the mean for
all other Pmps is only 13.9 [SE 2.3]. Cysteine residues are
responsible for the highly disulfide cross-linked proteins of the
outer membrane complex of EBs. Previous studies found that
PmpD is surface located and cross-linked in the chlamydial outer
Figure 3. Predicted pmpF promoter sequence for reference and clinical strains. Sequences are for reference strains E/Bour and L2/434, and clinical
strains E/537C-05, E/S-141, E/CS-500-96, and L2. The predicted transcription promoter for pmpF is located within a 100% conserved region of the
pmpG/pmpF IGR, where putative -10 and -35 elements are in blue characters and boxed. Potential A/T spacer region is underlined, and the predicted
transcription start site is shown in a larger font below a red asterisk. The putative RBS for pmpF is in orange characters, and the putative RNase E
cleavage sites are highlighted in grey. Numbers represent positions relative to the start codon of pmpF (highlighted in yellow). The start codon of
pmpG is highlighted in blue.
doi:10.1371/journal.pone.0000878.g003
Figure 4. Distribution/Location of the putative RNase E cleavage sites within the pmpFE operon coding sequence. The sequence is for reference
strains E/Bour and L2/434 and for clinical strains E/537C-05, E/S-141, E/CS-500-96 and L2. Black vertical lines represent all RNase E cleavage sites
conserved among all strains under study; green vertical lines show the ones only conserved among the four ‘‘E’’ strains; orange vertical lines represent
those specific solely for both L2 strains. Numbers represent nucleotide positions relative to the start codon of pmpF.
doi:10.1371/journal.pone.0000878.g004
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the N-terminal domain of C. pneumoniae Pmp21, the C. trachomatis
PmpD ortholog, was shown to be non-covalently bound to other
components of the EB surface [26]. Additionally, PmpD has
shown species-specific neutralizing activity [27]. These collective
data are supported by our findings that sera from C. trachomatis
infected patients were reactive to rPmpD (Fig. 5). Our results were
remarkably consistent for sera from patients infected with the same
strain. For example, sera from all eight patients infected with strain
E were reactive as were sera from three patients infected with
strain Ba and three infected with strain K, although only one of
the five patients with strain F were reactive; none of patients with
strains D, Ia, J or G were reactive. Additional research is required
to determine epitopes on PmpD that may correlate with the
differential immune responses we observed.
Overall, considering both reference strains and clinical strains,
pmpA and pmpI were the least expressed genes, while pmpF was the
most highly expressed, although pmpE and pmpG also had similar
expression levels for E/Bour. We previously found that PmpF is
the most polymorphic protein among the C. trachomatis Pmps for
both reference and clinical strains [28,12]. Consistent with the
observed protein diversity, phylogenetic analyses of PmpF grouped
C. trachomatis strains by tissue tropism properties [12]. Further,
comparative analyses of PmpF reveal distinct domains that may be
associated with a specific disease group.
The outer membrane exposure of the N-terminus has been
experimentally demonstrated for some C. pneumoniae Pmps [26,53],
suggesting that these proteins may be subjected to host immune
pressure. The N-terminal half for C. trachomatis PmpF also contains
numerous non-synonymous amino acid changes at locations of
predicted MHC epitopes [9], indicating that it may be involved in
eliciting a cellular immune response. Our findings that none of the
sera from infected patients reacted with rPmpF suggest that this
protein is not associated with the humeral immune response.
Strain origin (E/Bour) of rPmpF did not seem to be an issue as
sera from the eight patients infected with strain E were non-
reactive. Furthermore, sensitivity was unlikely to be an issue given
the immunoreactivity of the same sera with rPmpC and rMOMP,
as we have previously described [17], and with rPmpD in this
study. The occurrence of highly repeated GGAI motifs in the N-
terminus suggests that Pmps may be associated with cell adhesion
[54], which has been reported for Pmp21 of C. pneumoniae [26].
These cumulative findings suggest that Pmps are expressed with
a differential immune response for patients infected with a specific
strain. These findings and the remarkable pmpF expression
dissimilarities among L2/434, E/Bour and the clinical strains
suggest that there may be differential biological functions across
strains and within the same strain for PmpF, either as a structural
component to maintain membrane integrity, as part of a large pool
of polymorphic antigens to elicit cellular immunity, or as an
adhesin.
In our study, the pmpF sequences for the three clinical E strains
were found to be 100% similar to the E/Bour sequence as was L2
to L2/434. Since it is highly unlikely that identical proteins have
diverse functions, we hypothesized that there may be differential
regulation at the promoter level or regulation involving variations
in mRNA processing and/or degradation, which would yield
distinct mRNA amounts according to strain-specific needs. It is
well known that point mutations in regulatory regions, such as
promoter regions and RBS, can affect transcription and trans-
lation levels. However, analysis of the putative promoter region
and RBS for pmpF showed that they are 100% conserved for both
reference and the clinical strains (Fig. 3), suggesting that the
observed pmpF expression heterogeneity may result from variations
Table 2. Clinical and microbiologic characteristics of female adolescents from whom sera was used for determining the
immunoreactivity against rPmpD and rPmpF
..................................................................................................................................................
ompA genotype
a (n) Clinical diagnosis
b (n)
Immunoreactivity of sera against recombinant fusion proteins
rPmpD (%) rPmpF (%)
Ba (3) Cervicitis 3/3 (100) 0/3 (0)
D (3) Cervicitis Discharge
c (1/3) 0/3 (0) 0/3 (0)
E (8) Cervicitis 8/8 (100) 0/8 (0)
F (5) Cervicitis Discharge
c (4/5) 1/5 (20) 0/5 (0)
G (1) Cervicitis Discharge
c (1/1) 0/1 (0) 0/1 (0)
Ia (1) Cervicitis 0/1 (0) 0/1 (0)
J (2) Cervicitis 0/1 (0) 0/1 (0)
K (3) Cervicitis 3/3 (100) 0/3 (0)
Uninfected (13) No clinical signs or symptoms 0/13 (0) 0/13 (0)
aPatients were adolescents 14–19 years of age who had a C. trachomatis infection with only one ompA genotype as described in methods or were uninfected;
bThe diagnosis of cervicitis was based on physical findings consistent with cervicitis as determined by the examining physician; all adolescents infected with C.
trachomatis had cervicitis, and none of these patients complained of any symptoms;
cA cervical discharge was noted by the examining physician; none of these patients had clinical signs or symptoms consistent with upper genital tract disease.
doi:10.1371/journal.pone.0000878.t002
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Figure 5. Dot-Blot of serum immunoreactivity against recombinant
(r)PmpD and rPmpF. Sera was obtained from adolescents singly
infected and uninfected with a different C. trachomatis clinical strain as
described previously [17] (see also methods). rPmpD and rPmpF
concentrations were standardized for use on the blots. Immunoreac-
tivity to each fusion protein for sera from patients infected with strain
Ba (n=3), D (n=3), E (n=8), F (n=5), G (n=1), Ia (n=1), J (n=2) or K
(n=3) are shown. Of note is that immunoreactivity was consistent for
sera from patients infected with the same clinical strain except for strain
F (Table 2); all eight patients infected with strain E were reactive to
rPmpD.
doi:10.1371/journal.pone.0000878.g005
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systems of gene expression acting at both the transcriptional and
translational levels are well represented in the chlamydial genome,
including homologues of endoribonucleases E, III, G and P,
exoribonucleases II and PNPase, and oligoribonuclease [8,9].
These are known to control mRNA stability and processing as well
as translational efficiency in other bacteria, such as Escherichia coli
and Staphylococcus aureus [44,48,55–57]. The susceptibility of
mRNA to ribonuclease attack may be influenced by events
occurring not only at any stage during ribosome binding, but also
during translation elongation or termination [40].
We identified two conserved putative RNase E cleavage sites in
the pmpG/pmpF IGR, one of which is in close proximity to the
putative RBS (Fig. 3). It is known that RBS sequence variability
and sequestering by competitive regulatory proteins or conforma-
tional impediments can affect ribosome binding/loading and, thus,
mRNA lifetime [40]. Considering this, a hypothetical initial
cleavage by RNase E could reduce the affinity of the pmpF
translation initiation region for ribosomes, thereby allowing
subsequent mRNA degradation/processing by endo- and exonu-
cleases, preferentially for E/Bour when compared to the other
strains. A similar regulation has already been reported for sodB
mRNA of E. coli at low iron concentrations [58]. However, this
hypothetical mechanism, although possible, is speculative and
lacks experimental evidence.
pmpF and pmpE belong to the same operon, yet had remarkably
dissimilar mRNA levels for L2/434, and more so for all clinical
strains with up to 8.4-fold higher expression for pmpF than for
pmpE (Fig. 1A and 2). This did not occur for the pmpGH operon.
We speculated that the expression heterogeneity within the pmpFE
operon may be generated by premature termination of transcrip-
tion, rapid mRNA processing, or mRNA degradation primarily of
the downstream gene (pmpE) of this large operon transcript
(.6 Kb). Similar regulatory mechanisms have already been
suggested to explain the existence of multiple transcripts within
other bacterial policistronic operons [55], such as those of Bacillus
subtilis ara [59], Nitrosomonas europaea cbb [60], and Borrelia burgdorferi
ospAB and bmpAB [61,62].
Although we cannot assume that the putative stem-loop
structures found within the pmpFE operon sequence may act as
classic rho-independent type transcriptional terminators [49], the
possibility of hairpin formation (a common phenomenon in
mRNA, mainly on large transcripts) cannot be ignored nor can
its hypothetical processing role in mRNA degradation and
maturation be discounted. Furthermore, several putative RNase
E cleavage sites were identified throughout the pmpFE operon
(Fig. 4), which is expected for policistronic operons, although it is
well known that RNase E cleaves mRNA only at a limited number
of sites [55]. Interestingly, some of the RNase E sites were not
conserved between L2 and E strains, suggesting that targeted
mRNA degradation or rapid processing events may occur in this
large transcript. Curiously, one of these non-conserved recognition
sites involved solely the pmpF/pmpE IGR of the four E strains.
Thus, if RNase E uses this cleavage site, subsequent degradation or
processing events from this point would only occur for E strains
and could hypothetically yield an mRNA decay of pmpE. Yet, as
above, this mechanism is speculative and lacks experimental
evidence. However, in a previous study, differential transcript
quantities were reported for the MMSO genes of E. coli that
contained a consensus RNase E cleavage site in the intergenic
regions of the operon, suggesting complex mRNA processing [63].
Overall, the heterogeneous expression levels among pmps and
among strains highlight the importance of this gene family in
chlamydial biology. In particular, the unique expression disparity
for the pmpFE operon with relatively high pmpF mRNA levels for 5
of the 6 strains under study, as well as the differential
immunoreactivity of patient sera to rPmpD, suggest that some
Pmps may explain phenotypic differences among strains for
antigenicity, virulence and tissue tropism. Furthermore, our
findings that clinical E strains do not correlate with reference
strain E/Bour at the gene expression level are supported by our
previously reported genomic data [28], reinforcing the need to
examine clinical along with reference strains to advance our
understanding of the role of pmps in chlamydial biology and
disease pathogenesis.
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